Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4329-4334

  Parra Ruiz, Jorge ^a,b   Vidaillac, Celine ^a   Rose, Warren E ^c   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Infectious Diseases Unit   (Spain)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; DAPTOMYCIN; MOXIFLOXACIN; POLYSTYRENE; RIFAMPICIN; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM; BACTERIUM ISOLATION; BIOFILM; BIOFILM REACTOR; BODY WEIGHT; COLONY FORMING UNIT; DRUG MEGADOSE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BIOFILMS; CLARITHROMYCIN; DAPTOMYCIN; MICROSCOPY, ELECTRON, SCANNING; QUINOLINES; RIFAMPIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 77957360799     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00455-10     Document Type: Article

References (37)

1. Aslam, S. 2008. Effect of antibacterials on biofilms. Am. J. Infect. Control 36:S175.e9-S175.e11.
2. Balfour, J. A., and L. R. Wiseman. 1999. Moxifloxacin. Drugs 57:363-373.
3. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
4. Ceri, H., M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
5. Cha, R., W. J. Brown, and M. J. Rybak. 2003. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 47:3960-3963.
6. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Costerton, J. W., L. Montanaro, and C. R. Arciola. 2005. Biofilm in implant infections: its production and regulation. Int. J. Artif. Organs 28:1062-1068.
8. Falagas, M. E., A. M. Kapaskelis, V. D. Kouranos, O. K. Kakisi, Z. Athanassa, and D. E. Karageorgopoulos. 2009. Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs 69:1351-1361.
9. Figueroa, D. A., E. Mangini, M. Amodio-Groton, B. Vardianos, A. Melchert, C. Fana, W. Wehbeh, C. M. Urban, and S. Segal-Maurer. 2009. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49:177-180.
10. Frank, K. L., E. J. Reichert, K. E. Piper, and R. Patel. 2007. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob. Agents Chemother. 51:888-895.
11. Fujimura, S., T. Sato, T. Mikami, T. Kikuchi, K. Gomi, and A. Watanabe. 2008. Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. Int. J. Antimicrob. Agents 32:481-484.
12. Fux, C. A., P. Stoodley, L. Hall-Stoodley, and J. W. Costerton. 2003. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev. Anti Infect. Ther. 1:667-683.
13. Gander, S., A. Kinnaird, and R. Finch. 2005. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56:337-343.
14. Goeres, D. M., L. R. Loetterle, M. A. Hamilton, R. Murga, D. W. Kirby, and R. M. Donlan. 2005. Statistical assessment of a laboratory method for growing biofilms. Microbiology 151:757-762.
15. Hajdu, S., A. Lassnigg, W. Graninger, A. M. Hirschl, and E. Presterl. 2009. Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. J. Orthop. Res. 27:1361-1365.
16. John, A. K., D. Baldoni, M. Haschke, K. Rentsch, P. Schaerli, W. Zimmerli, and A. Trampuz. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
17. Kullar, R., S. Davis, D. P. Levine, et al. 2009. Safety of high-dose daptomycin for gram-positive infections, abstr. 1983. Abstr. 49th. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009. American Society for Microbiology, Washington, DC.
18. LaPlante, K. L., and L. A. Mermel. 2007. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol. Dial. Transplant. 22:2239-2246.
19. LaPlante, K. L., and S. Woodmansee. 2009. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob. Agents Chemother. 53:3880-3886.
20. Lauderdale, K. J., B. R. Boles, A. L. Cheung, and A. R. Horswill. 2009. Interconnections between sigma B, agr, and proteolytic activity in Staphylococcus aureus biofilm maturation. Infect. Immun. 77:1623-1635.
21. Lichterfeld, M., M. J. Ferraro, and B. T. Davis. 2010. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. Int. J. Antimicrob. Agents 35:96.
22. Mah, T. F., and G. A. O'Toole. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9:34-39.
23. McLeod, B. R., and E. L. Sandvik. 2010. A biofilm growth protocol and the design of a magnetic field exposure setup to be used in the study of magnetic fields as a means of controlling bacterial biofilms. Bioelectromagnetics 31:56-63.
24. Moise, P. A., E. Hershberger, M. I. Amodio-Groton, and K. C. Lamp. 2009. Safety and clinical outcomes when utilizing high-dose (≥ 8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43:1211-1219.
25. Monzon, M., C. Oteiza, J. Leiva, and B. Amorena. 2001. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J. Antimicrob. Chemother. 48:793-801.
26. Morikawa, K., A. Maruyama, Y. Inose, M. Higashide, H. Hayashi, and T. Ohta. 2001. Overexpression of sigma factor, sigma(B), urges Staphylococcus aureus to thicken the cell wall and to resist beta-lactams. Biochem. Biophys. Res. Commun. 288:385-389.
27. Otto, M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228.
28. Patel, R. 2005. Biofilms and antimicrobial resistance. Clin. Orthop. Relat. Res. 437:41-47.
29. Perez-Giraldo, C., C. Gonzalez-Velasco, R. M. Sanchez-Silos, C. Hurtado, M. T. Blanco, and A. C. Gomez-Garcia. 2004. Moxifloxacin and biofilm production by coagulase-negative staphylococci. Chemotherapy 50:101-104.
30. Raad, I., H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, G. Chaiban, R. Sherertz, and R. Hachem. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-1660.
31. Rose, W. E., and P. T. Poppens. 2009. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63:485-488.
32. Roveta, S., A. Marchese, and G. C. Schito. 2008. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int. J. Antimicrob. Agents 31:321-328.
33. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
34. Sakoulas, G., G. M. Eliopoulos, J. Alder, and C. Thauvin-Eliopoulos. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718.
35. Sano, M., T. Hirose, M. Nishimura, S. Takahashi, M. Matsukawa, and T. Tsukamoto. 1999. Inhibitory action of clarithromycin on glycocalyx produced by MRSA. J. Infect. Chemother. 5:10-15.
36. Stewart, P. S., and J. W. Costerton. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
37. Yasuda, H., Y. Ajiki, T. Koga, and T. Yokota. 1994. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob. Agents Chemother. 38:138-141.